Autopsy report · NCT05349760

A Phase 2 Study to Evaluate Safety and Efficacy of AMB-05X in Subjects With Idiopathic Pulmonary Fibrosis

“to focus resources on other studies”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 2

Sponsor

AmMax Bio, Inc.

Sponsor type

Industry

Conditions

IPF

Interventions

AMB-05X; Placebo

Participants

0

Trials that died the same way

• Azacitidine and Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia
  “Due to limited resources available to conduct study” (60% match in meaning)
• Safety and Efficacy Study of NovoRapid™ in Patients With Coexisting Diabetes and Kidney Disease
  “Due to company decision to focus resources on the finalisation of three ongoing studies in the region” (58% match in meaning)
• Remote Monitoring of Respiratory Health
  “Resources not available to continue study” (57% match in meaning)
• Talimogene Laherparepvec in Treating Patients With Non-Muscle Invasive Bladder Transitional Cell Carcinoma
  “Investigators prefer to pursue other studies” (57% match in meaning)
• Use of NAVA in Intubated Preterm
  “Another institution performed the study” (57% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.